Jasper Therapeutics, Inc. — Form 8-K Summary
Reporting event: Special stockholder meeting held September 30, 2026; the 8-K was signed October 5, 2026.
Business context and meeting results
Jasper Therapeutics reported voting results on three proposals. Of 33,274,561 shares outstanding on the August 10, 2026 record date, 21,747,865 shares—approximately 65.36%—were represented at the meeting. Stockholders approved all three proposals.
- Reverse stock split: Approved an amendment permitting the Board, in its sole discretion, to implement a 1-for-15 to 1-for-35 reverse split (or an intermediate ratio) on or before December 31, 2026. The split would not reduce the authorized number of common shares and would not require further stockholder approval. Votes: 21,088,353 for; 567,692 against; 91,820 abstentions.
- Authorized share increase: Approved an amendment permitting the Board, in its sole discretion, to increase authorized common shares from 490,000,000 to 675,000,000. Votes: 20,722,644 for; 903,655 against; 121,566 abstentions.
- Adjournment: Approved authority to adjourn the meeting, if necessary, to solicit additional proxies for the reverse split or authorized share increase proposals. Votes: 20,938,915 for; 528,123 against; 280,827 abstentions.
Financial performance and liquidity
This filing reports meeting outcomes, not financial results. It does not provide revenue, profit, cash flow, margins, debt, liquidity, or financial guidance.
Material changes, outlook, and risks
The approved proposals provide the Board with discretion over a potential reverse split and a potential increase in authorized common shares. The filing does not state that either action has been implemented, specify the reverse-split ratio, or provide additional management commentary, financial outlook, or contingencies.
Investor facts to verify
- Whether and when the Board implements a reverse split, and the ratio selected before the December 31, 2026 deadline.
- Whether the authorized-share increase is effected and how the additional authorized shares may be used.
- Any subsequent company disclosures describing the timing or effects of these capital-structure actions.